Since last October, Singulair allergy and asthma medication labels have warned that the drug is linked to, “suicidal thinking and behaviour.” The Wall Street Journal reports:
Singulair, made by Merck & Co., is approved to treat asthma and allergy symptoms such as sneezing and stuffy noses, as well as to prevent exercise-induced asthma. The FDA said in a so-called early communication that it is reviewing postmarketing reports of behavior and mood changes, suicidal thoughts and actions, and actual suicides by patients who took Singulair. The regulator also asked Merck to look at its own database for signs of trouble.
Early communications are a recently developed tool the FDA uses to tell consumers and health-care professionals that the agency is looking into a particular safety concern but that it hasn’t reached any conclusions.
Jump to full WSJ article.